Plain-English translation of NCT06924606 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new medication called JS207, which works as a dual antibody—meaning it targets two different pathways in cancer cells at the same time. Researchers want to see if JS207, given alone or combined with other approved drugs, can help slow or shrink advanced lung cancer in people whose cancer continued to grow after previous chemotherapy and immunotherapy treatments.
Many people with advanced lung cancer see their cancer progress even after receiving standard chemotherapy combined with immunotherapy drugs. This trial exists to find out whether this new treatment approach can help patients whose cancer has stopped responding to current standard options.
You likely qualify if…
You likely don't qualify if…
You will be assigned to one of three treatment groups: one receiving the new medication combined with docetaxel chemotherapy, one receiving it combined with another drug called JS004, or one receiving the new medication alone. All treatments are given as infusions every three weeks. You will have regular visits for scans, blood tests, and check-ins to monitor how the treatment is working and any side effects you may experience.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China